Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT61 with Bactroban and Naseptin for nasal Staphylococcus aureus carriage
2011-002438-38Phase 2Terminated
- Sponsor
- Helperby Therapeutics
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HT61 in Staphylococcus aureus carriage, staphylococcal carrier state and Staphylococcus aureus infection, sponsored by Helperby Therapeutics. Primary endpoint: Time to 99% reduction in nasal Staphylococcus aureus colony forming units. Started Feb 2012; status: terminated.
02
Drugs
HT61
03
Conditions
Staphylococcus aureus carriagestaphylococcal carrier stateStaphylococcus aureus infection
Beyond the preview
Go deeper on 2011-002438-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002438-38.